News

BioStat® Research
& Development Centre

2025 2024 2023 older
New Knowledge Base on Clinical Trials
14
November
2025
New Knowledge Base on Clinical Trials
For several years now, the Biostat Research and Development Center has operated as a Full-Service CRO – a...
Voice Assistant for Doctors – A New AI Feature in the Medfile Program
29
July
2025
Voice Assistant for Doctors – A New AI Feature in the Medfile Program
Biostat's developers are launching a Voice Assistant for doctors in the Medfile software designed for medical fac...
Clinical Trial of an Innovative Intramedullary Nail
16
July
2025
Clinical Trial of an Innovative Intramedullary Nail
The Biostat Research and Development Center will conduct a multicenter, open-label clinical trial aimed at evaluating...
Biostat with EcoVadis CSR Certificate
08
July
2025
Biostat with EcoVadis CSR Certificate
The Biostat Research and Development Center has received the EcoVadis certification and the Silver Medal. EcoVadi...
New AI Solutions in Medfile
28
May
2025
New AI Solutions in Medfile
The Biostat development team is constantly enhancing the Medfile software for managing medical facilities. Recently, ...
Patient Assistant. Another AI-Based Solution in Medfile
06
February
2025
Patient Assistant. Another AI-Based Solution in Medfile
Patient Assistant is another AI-based solution in Medfile, following Drug Assistant. Thanks to this feature, patients...
6 million users of Medfile and HaloDoctor medical services
08
January
2025
6 million users of Medfile and HaloDoctor medical services
Nearly 6 million unique users visited the health websites Medfile.pl and HaloDoctor.pl, published by Biostat. Both po...
22
July
2022
Biostat® supports studies on depression treatment
22
July
2022

Biostat® supports studies on depression treatment

The Biostat® Research and Development Center supports the development of the treatment of depression and anxiety disorders. Biostat® will take part in a study carried out by specialists from the Medical University of Gdańsk on the effect of sertraline on progress in the treatment of depression and anxiety disorders in patients with heart failure.

Depression is one of the most common mental illnesses. As specialists explain, due to the growing percentage of people suffering from depression, it is estimated that by 2030 global sales of anxiolytics and antidepressants will increase by 37%. The main risk factors for depression and anxiety disorders are age, low socioeconomic status and the presence of chronic diseases, including heart disease. Therefore, patients with heart failure are a group particularly vulnerable to depression and anxiety disorders.1

We are pleased to inform you that the Biostat® Research and Development Center has concluded an agreement with the Medical University of Gdańsk. Biostat® will support specialists from GUM and other medical sites in the management of a non-commercial clinical trial that will examine the effect of sertraline on progress in the treatment of depression and anxiety disorders in patients with heart failure with preserved ejection fraction and on the broadly understood condition of these patients.

 

This is yet another cooperation between Biostat® and the largest medical university in northern Poland. We are proud of the fact that our customers appreciate the commitment and professionalism of Biostat® employees, which results in a wide range of regular customers - emphasizes Edyta Klemba - Pharma Division Director at Biostat®

 

Additionally, a few weeks ago, Biostat® signed an agreement with the Silesian Center for Heart Diseases in Zabrze for a non-commercial study focused on the treatment of cardiovascular diseases.

 

See also: noncommercial clinical trials conducted by BioStat.

1 Source: website of the Medical University of Gdańsk

 

> Learn more about Biostat's clinical research services

 

Copyright© 2023 Biostat